Benzinga | Oct 12, 2021 08:03AM EDT

Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $242

Morgan Stanley analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $234 to $242.